Please login to the form below

Not currently logged in
Email:
Password:

EvaluatePharma

This page shows the latest EvaluatePharma news and features for those working in and with pharma, biotech and healthcare.

FDA turns down Celgene’s filing for multiple sclerosis drug

FDA turns down Celgene’s filing for multiple sclerosis drug

A recent EvaluatePharma reported suggested the drug could achieve sales of around $1.8bn in 2022.

Latest news

More from news
Approximately 3 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    A recent analysis through 2015 made by EvaluatePharma shows that six of the top ten pharma companies will derive less than 20% of drug sales from products that were developed from

  • Pharma deals during February 2014 Pharma deals during February 2014

    The lustre of orphans continue. The orphan drug space continues-to-attract, not surprising given EvaluatePharma's estimate that orphan drug sales totalled $92bn in 2012, and will grow 8 per

  • Interview: Yoshihiko Hatanaka, CEO and president, Astellas Interview: Yoshihiko Hatanaka, CEO and president, Astellas

    According to the business intelligence database, EvaluatePharma, the company earned $1.37bn in 2010 from what was the world's best-selling drug, but these revenues are expected to halve by ... That was considered key to play within the pharmaceutical

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics